



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

HA (H3N2)(aa 17-529) (A/PERTH/16/2009)

CATALOG NUMBER: IA-0045W-005P, 50 µg

Introduction

Influenza hemagglutinin (HA) is a type of hemagglutinin found on the surface of the influenza viruses. HA is an antigenic glycoprotein, like all other hemagglutinins, it causes red blood cells to agglutinate. HA is responsible for binding the virus to the cell that is being infected. HA proteins bind to cells with sialic acid on the membranes, such as cells in the upper respiratory tract or erythrocytes.

HA is a homotrimeric integral membrane glycoprotein. HA monomer is synthesized as a single polypeptide that is subsequently cleaved into two smaller polypeptides, the HA1 and HA2 subunits. Each HA monomer consists of a long, helical chain anchored in the membrane by HA2 and topped by a large HA1 globule.

Description

Viral protein purified from 293 cell culture.

Viral Protein

C-terminal 6xHis tagged HA(A/Perth/16/2009/H3N2) protein (amino acid 17-529) (GenBank Accession#: ACS71642)

Applications

Western blot standard, antibody ELISA, antigen, etc.

Storage

Store at -20 °C; Stable for 3-months from the date of shipment when kept at 4 °C. Non-hazardous. No MSDS required.

Concentration


1 µg/µl in PBS

Endotoxin Level

<0.01 EU per 1 µg of the protein by LAL test

Purity

≥ 95% purity (SDS PAGE)



SDS-PAGE: purified HA (H3N2)(A/Perth/16/2009)(aa18-529) protein

HA SEQ:

QKLPGNDNSTATLCLGHHAVPNGTIVKTIITNDQIEVTNATELVQSSSTGEICDSPHQILDGKNCTLIDALLGDPQCDSGFQNKKWDLFVE
RSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNE SFNWTGVTQNGTSSACIRRSKNSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLY
IWGVHHPGTDKDQIFLYAQASGRITVSTKRSQQTVSPNIGSRPRVRNIPSRISIIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSI
MRSDAFIGKCNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRHQ
NSEGRGQAADLKSTQAAIDQINGKLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEM
NKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDHHHHHH

Reference

1. Pebody R, etc. Euro Surveill. 18(5), 20389, 2013
2. Loebermann M, etc. Vaccine. 29 (6), 1228, 2011